Loading...
•
Dec 31, 2024
Esperion Q4 2024 Earnings Report
Esperion reported strong Q4 2024 results with 114% revenue growth and narrowed losses.
Key Takeaways
Esperion's Q4 2024 revenue increased 114% year-over-year to $69.1 million, driven by strong prescription growth. The company's net loss improved significantly to $21.3 million from $56.3 million in Q4 2023. The company continues to expand globally and develop new combination therapies.
Q4 2024 revenue grew 114% Y/Y to $69.1 million.
Net loss improved to $21.3 million from $56.3 million in Q4 2023.
U.S. net product revenue increased 52% Y/Y to $31.6 million.
Esperion initiated development of triple combination products with bempedoic acid.
Esperion
Esperion
Esperion Revenue by Segment
Revenue by Segment
U.S. Net Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Esperion expects continued revenue growth, supported by global expansion and new combination therapies. The company aims to reach operating profitability while navigating financial and regulatory challenges.
Positive Outlook
- Continued revenue growth driven by increased prescription volume.
- Expansion into Japan, Canada, and Israel with new regulatory filings.
- Development of triple combination therapies with bempedoic acid.
- Strengthened balance sheet following financial restructuring.
- Increased market penetration with broader insurance coverage.
Challenges Ahead
- Operating expenses projected to remain high in 2025.
- Continued net losses expected in the near term.
- Potential pricing pressures in international markets.
- Regulatory approvals in new markets may face delays.
- Competitive landscape in cardiovascular therapies remains challenging.
Revenue & Expenses
Visualization of income flow from segment revenue to net income